| Document |
Document Title |
|
JP4705093B2 |
The present invention relates compounds of the formula A oligosaccharide-spacer-GpIIb/IIIa antagonist wherein the oligosaccharide is a negatively charged oligosaccharide residue comprising four to twenty five monosaccharide units, the ch...
|
|
JP4703950B2 |
|
|
JP4688414B2 |
Preparation of synthetic monosaccharides, disaccharides and trisaccharides for use in the preparation of synthetic heparinoids.
|
|
JP2011084517A |
To provide an inhibitor of natural immune response which is activated by a nucleic acid and a screening method.The inhibitor of natural immune response which is activated by a nucleic acid includes a compound selected from the group cons...
|
|
JP4676049B2 |
|
|
JP4676048B2 |
|
|
JP4675048B2 |
|
|
JP4659209B2 |
A pharmaceutical agent for treating an amyloid disease in a patient, wherein the pharmaceutical agent comprises a saccharide containing at least one substituted anionic group, or a pharmaceutically acceptable salt of the saccharide conta...
|
|
JP4658807B2 |
A method for producing 2'-deoxy-2'-fluoro-²-D-arabinonucleoside represented by formula (II): (wherein B represents a base), in particular, 2'-deoxy-2'-fluoro-²-D-arabinopurinenucleoside, which method comprises causing a nucleoside phos...
|
|
JP4634027B2 |
To obtain an alternative agent for vitamin D-like activity that can safely be ingested for a long period of time. This alternative agent for vitamin D-like activity contains a sugar phosphate ester or its salt as an active ingredient. In...
|
|
JP2010285446A |
To provide processes for producing alkylamino glucosaminide phosphate compounds and disaccharide compounds functioning as immunoeffectors or adjuvants intended for vaccines and the like comprising various novel intermediates and intermed...
|
|
JP4585172B2 |
|
|
JP2010235593A |
To provide a useful sugar 1-boranophosphate compound, and to provide a method for producing the same.The method for producing a compound represented by general formula (I) [wherein, R1 and R2 are each alkyl; and R-O- is a sugar compound ...
|
|
JP4567887B2 |
The present invention relates to a method and materials for producing glucosamine by fermentation of a genetically modified microorganism. Included in the present invention are genetically modified microorganisms useful in the present me...
|
|
JP2010166934A |
To provide a method and materials for producing glucosamine by fermentation of a genetically modified microorganism.Included in the present invention are genetically modified microorganisms useful in the present method for producing gluc...
|
|
JP4518867B2 |
|
|
JP4514240B2 |
PCT No. PCT/AU96/00238 Sec. 371 Date Oct. 28, 1997 Sec. 102(e) Date Oct. 28, 1997 PCT Filed Apr. 24, 1996 PCT Pub. No. WO96/33726 PCT Pub. Date Oct. 31, 1996Sulfated oligosaccharides, wherein the oligosaccharide has the general formula I...
|
|
JP4485169B2 |
The present invention relates to an intestinal mineral absorption capacity improver containing glucose 1-phosphate sodium salt as an effective ingredient.
|
|
JP4464272B2 |
The object of the present invention is to provide a nucleoside or nucleotide having an unnatural base. The nucleoside or nucleotide of the present invention has a 5-substituted-2-oxo(1H)-pyridin-3-yl group as a base. Preferably, the 5-po...
|
|
JPWO2008090631A1 |
Eliminates problems related to fucoidan absorbability, antigenicity, uniformity, anticoagulant activity, etc. that occur when developing fucoidan, which is a sulfated polysaccharide with an extremely large molecular weight, as a pharmace...
|
|
JP2010510190A |
The present invention relates to a novel process for the chemical synthesis of β-(1->6)-linked glucosamine disaccharides of the formula (1) and (intermediate) compounds relating to the process. According to further aspects the invention...
|
|
JP4429386B2 |
A keratan sulfate oligosaccharide which comprises from two to five sugar units and has sulfated N-acetylglucosamine at the reducing end and in a molecule of which at least two hydroxyl groups are sulfated, preferably, which contains at l...
|
|
JP2010505813A |
The present invention is concerned with anticoagulants ( i.e. substances that stop blood from clotting). More specifically, the present invention is concerned with orally available antithrombic oligosaccharides.
|
|
JP2010031037A |
To provide a method for producing an anomer-selective 1-phosphorylated saccharide derivative and a nucleoside, effected with neither skeletal difference, such as furanose and pyranose, existence of substituents, such as deoxysugar, nor k...
|
|
JP4410913B2 |
The present invention is a compound of general formula (I) or a pharmaceutically acceptable salt of,wherein W represents carbon chain from 9 to 17 which containing double bond or hydroxy group occasionally; X represents carbon chain from...
|
|
JP2010024213A |
To provide a method for selectively producing a stereoisomer of an anomer position of a saccharide 1-phosphoric acid compound.The method for producing a saccharide 1-phosphoric acid compound represented by formula (I): R-X-P(R1)(R2) (R i...
|
|
JP2010503619A |
The glmS riboswitch is a target for antibiotics and other small molecule therapies. Compounds can be used to stimulate, active, inhibit and/or inactivate the glmS riboswitch. The atomic structures of the glmS riboswitch can be used to de...
|
|
JP4370162B2 |
The present invention relates to novel solid-phase processes for the production of radiolabelled tracers, in particular for the production of <18>F-labelled compounds which may be suitable for use as Positron Emission Tomography (PET) ra...
|
|
JP4364959B2 |
The invention relates to a carbohydrate derivative having formula Iwherein R1 is (1-4C)alkoxy; R2, R3 and R4 are independently (1-4C)alkoxy or OSO3-, the total number of sulfate groups is 4, 5, or 6; and the twisted lines represent bonds...
|
|
JP2009235085A |
To provide new sulfated oligosaccharides and use thereof.Provided are sulfated oligosaccharides, wherein the oligosaccharide is represented by general formula (I): R1-(Rx)n-R2 (wherein, R1 and R2 and each Rx represent a monosaccharide un...
|
|
JP4331917B2 |
|
|
JP4299378B2 |
Inositol glycan derivatives of formula (I), their salts and stereoisomeric forms, are new: A-Z-R (I) A = HP(=O)(OH), HP(=S)(OH), HOP(=S)(OH), HSP(=S)(OH), (1-4C alkyl)P(=O)(OH), (1-4C alkyl)P(=S)(OH), SO2ORl, S(=O)OR1, NH2CO, NR1R2, R1R2...
|
|
JP4278118B2 |
To obtain new phosphatase KU-8 capable of recognizing the bond position of phosphate group of phosphorylated saccharide and carrying out dephosphorylation, to efficiently and readily obtain a 3-phosphrylated saccharide from a phosphoryla...
|
|
JP4262601B2 |
An enzyme capable of degrading sulfated fucan originating in a brown alga of Fucales which is useful in sugar chain engineering; a process for producing this enzyme; an oligosaccharide obtained by treating sulfated fucan with the enzyme;...
|
|
JP4251410B2 |
Anticonvulsant derivatives useful in treating psoriasis are disclosed. 00000
|
|
JP2009511544A |
The present invention relates compounds of the formula I: oligosaccharide-spacer-GpIIb/IIIa antagonist I, wherein the oligosaccharide is a negatively charged pentasaccharide residue of the structure (I), the charge being compensated by p...
|
|
JP4237257B2 |
A process and use of at least one catalyst for phosphorylation, in particular phosphitylation, of hydroxyl groups, whereby a phosphorous compound is added to a hydroxyfunctional compound having at least one hydroxyl group. The addition y...
|
|
JP2009019044A |
To use a keratan sulfate oligosaccharide essentially free from impurities as a pharmaceutical composition, an anti-inflammatory agent, an antiallergic agent, an immunomodulator, a cell differentiation inducer or an apoptosis inducer.The ...
|
|
JP2008545800A |
Described are novel processes for the synthesis triflated sugars. These sugars are useful for the production of compounds, such as D-1-deoxynojirimycin (DNJ) and D-1-deoxygalactonojirimycin (DGJ). In particular, described is a multi-kilo...
|
|
JP2008542237A |
The present invention concerns a liquid preconcentrate composition comprising topiramate or a pharmaceutically acceptable addition salt thereof as active ingredient and an organic solvent, said composition having a low water content; a l...
|
|
JP4187072B2 |
Therapeutic compounds and methods for inhibiting amyloid deposition in a subject, whatever its clinical setting, are described. Amyloid deposition is inhibited by the administration to a subject of an effective amount of a therapeutic co...
|
|
JP2008540398A |
An oligosaccharide useful for a Meningitidis A vaccine contains a first mannose unit having a spacer in the alpha configuration at C-1, which spacer is capable of conjugating to a protein, and which is connected to a second mannose unit ...
|
|
JP4182219B2 |
|
|
JP4178584B2 |
|
|
JP4166273B2 |
The present invention provides a process for synthesizing a compound having the structure: ides useful as a vaccine for inducing antibodies to human breast cancer cells in an adjuvant therapy therefor.
|
|
JP2008239625A |
To provide a medicine composition for promoting healing of a hurt accompanied by reduction of scars or a fibrous disorder.The medicine composition composed of fructose-1-phosphate as an active ingredient, a pharmaceutically acceptable ca...
|
|
JP4145494B2 |
Compounds represented by general formula (I) wherein X represents OH or OSO3H; and R represents a substituent other than OH which allows, after leaving, the induction of unsaturated bonds into the 3- and 4-positions of 3,6-anhydrogalacto...
|
|
JP2008195667A |
To provide a 2-6 sialyl 6-sulfo sugar chain compound bonded with a lipid, or its salt, usable as an anticancer agent and an immunoregulating agent.This compound having a 2-6 sialyl 6-sulfo sugar chain bonded with cholestanol, cholesterol...
|
|
JP4132233B2 |
|
|
JP4097294B2 |
The present invention describes a method for treating neuropathic pain comprising administering to a mammal afflicted with such condition a therapeutically effective amount for treating such condition of a compound of formula (I), wherei...
|
